title: [Treatment of venous thromboembolic disease using low molecular weight CY216 heparin in patients with high risk of hemorrhage].
authors.forename: P
authors.initials: P
authors.lastname: Prandoni
authors.forename: M
authors.initials: M
authors.lastname: Vigo
authors.forename: P F
authors.initials: PF
authors.lastname: Tropeano
authors.forename: E
authors.initials: E
authors.lastname: Carletti
authors.forename: F
authors.initials: F
authors.lastname: Corbetti
authors.forename: G
authors.initials: G
authors.lastname: Antonello
authors.forename: S
authors.initials: S
authors.lastname: Cuppini
mesh_terms: D000328:Adult; D000368:Aged; D004334:Drug Administration Schedule; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced / Q000517:prevention & control*; D006493:Heparin / Q000009:adverse effects; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D011655:Pulmonary Embolism / Q000188:drug therapy*; D012307:Risk Factors; D013924:Thrombophlebitis / Q000188:drug therapy*
chemical_list: D006495:Heparin, Low-Molecular-Weight; D006493:Heparin
vernacular_title: Terapia della malattia tromboembolica venosa con eparina a basso peso molecolare CY216 in pazienti ad alto rischio di emorragia.